Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967805 | 0.95 | CHRNB4 (0.57) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL22097298 | 0.86 | CHRNB4 (0.50) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL2045328 | 0.77 | CHRNB4 (0.57) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL24414772 | 0.74 | CHRNB4 (0.55) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL2299673 | 0.72 | KIF11 (0.55) | CYP1A2KIF11KDM1AKCNH2KDM1B | |
| SCHEMBL16098695 | 0.72 | CHRNB4 (0.66) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL433117 | 0.71 | CHRNB4 (0.90) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL2807123 | 0.71 | CHRNB4 (0.90) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL18985115 | 0.71 | CHRNB4 (0.67) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB | |
| SCHEMBL12021901 | 0.71 | CHRNB4 (0.53) | CHRNB4CHRNA3CYP1A2ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | claimed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | claimed |
| CN-109608464-B | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | claimed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | claimed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | claimed |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | SHANGHAI UNIVERSITY OF MEDICINE & HEALTH SCIENCES (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI UNIVERSITY OF MEDICINE&HEALTH SCIENCES (CN) | 2022-03-10 | — | — | US | disclosed |
| CN-109608464-B | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119206-A1 | RADIOACTIVE IODINE-LABELLED LAROTRECTINIB COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海健康医学院 | 2020-06-18 | — | — | WO | disclosed |
| CN-109608464-A | A kind of radioiodination Larotrectinib compound and its preparation method and application | 上海健康医学院 | 2019-04-12 | — | — | CN | disclosed |
| CN-101998959-B | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARM INC | 2013-08-28 | — | — | CN | disclosed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| CN-101998959-A | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | LEAD THERAPEUTICS INC | 2011-03-30 | — | — | CN | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072164-A1 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885CYP1A2 2871/4885 |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | CHRNB4 4583/4885CHRNA3 3682/4885CYP1A2 577/4885 |
| US-12161731-B2 | Radioactive I-labeled larotrectinib compound and preparation method and application thereof | IGF1R, TSHR, TRHR | CHRNB4 2453/4885CHRNA3 3061/4885CYP1A2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.